Development and Characterization of Immunotherapies for HPV-Associated Malignancies

项目总结/摘要 约翰霍普金斯大学医学院宫颈癌研究实验室（CCRL）专注于 开发疫苗和新的免疫策略，用于预防和治疗人类 乳头瘤病毒（HPV）相关疾病。Shiwen Peng博士是一位敬业的研究专家， CCRL的成员。彭博士在免疫学、癌症生物学和翻译方面有很强的背景。 研究，在疫苗开发和HPV相关癌症方面拥有广泛的培训和经验 免疫疗法自2003年首次加入CCRL作为研究助理以来，彭博士已经取得了许多成就。 为开发预防和治疗HPV的创新免疫疗法做出贡献- 相关疾病。值得注意的是，彭博士是第一个开发针对HPV 16 E6蛋白的DNA疫苗的人。 他还与其他实验室成员和研究人员合作，确定了多种新颖的策略， 增强免疫疗法的功效，包括通过基因枪输送我们的DNA疫苗。这项建议是 旨在支持Shiwen Peng博士在几个CCRL研究项目中的作用，包括开发 HPV相关的宫颈癌和口咽癌的新的临床前肿瘤模型，人类 用于人体临床试验的免疫学测定，以及相关临床前数据的生成 作为进一步临床翻译的基础。为了实现这一目标，彭博士将测试免疫疗法， HPV相关疾病在新型临床前肿瘤模型中的应用，以改善患者的癌症免疫治疗， 率先努力开发用于HPV相关临床试验的人体免疫学检测方法， 癌症患者。到目前为止，彭博士已经成功开发了新的候选疫苗，疫苗接种策略， 以及用于体内疫苗评估的新免疫学测定。彭博士曾与吴博士密切合作 自2004年成立以来，她一直担任宫颈癌孢子的共同研究员。他继续参与 CCRL和与其他研究人员的合作使他能够开发创新技术， 为CCRL的成功做出了贡献。彭博士有设计和执行实验的天赋， 与一些研究人员合作，并在智力上有助于几个赠款申请和同行- 审查出版物。他将参加并出席几个会议，以介绍创新的想法 CCRL，并提高他的技能，专业知识和HPV相关疾病的知识。

Project Summary/Abstract The Johns Hopkins University School of Medicine Cervical Cancer Research Lab (CCRL) is focused on developing vaccines and novel immunotherapeutic strategies for the prevention and treatment of human papillomavirus (HPV)-associated diseases. Dr. Shiwen Peng is a dedicated Research Specialist and essential member of the CCRL. Dr. Peng has a strong background in immunology, cancer biology, and translational research, with extensive training and experience in vaccine development and HPV-associated cancer immunotherapy. Since he first joined the CCRL as a Research Associated in 2003, Dr. Peng has made numerous contributions towards developing innovative immunotherapies for the prevention and treatment of HPV- associated diseases. Notably, Dr. Peng was the first to develop a DNA vaccine targeting the HPV16 E6 protein and has also collaborated with other lab members and investigators to identify multiple novel strategies to enhance efficacy of immunotherapies, including the delivery of our DNA vaccine via gene gun. This proposal is designed to support Dr. Shiwen Peng’s role on several CCRL research programs, including the development of novel preclinical tumor models of HPV-associated cervical and oropharyngeal cancers, development of human immunological assays intended for translation to human clinical trials, and generation of relevant preclinical data to serve as foundation for further clinical translation. To achieve this goal, Dr. Peng will test immunotherapies for HPV-associated diseases in novel preclinical tumor models to improve cancer immunotherapy for patients and spearhead efforts to develop human immunological assays employed in clinical trials involving HPV-associated cancer patients. To date, Dr. Peng has successfully developed new vaccine candidates, vaccination strategies, and new immunological assays for the evaluation of vaccines in vivo. Dr. Peng has worked closely with Dr. Wu as a co-investigator on the Cervical Cancer SPORE since its inception in 2004. His continued involvement in the CCRL and collaborations with other investigators has allowed him to develop innovative technologies that have contributed to the success of the CCRL. Dr. Peng has the innate ability to design and perform experiments, collaborate with a number of investigators, and intellectually contribute to several grant applications and peer- reviewed publications. He will participate and present in several conferences in order to introduce innovative ideas to the CCRL and enhance his skills, expertise, and knowledge of HPV-associated diseases.